Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 47.22 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $71.430 million which missed the analyst consensus estimate of $78.396 million by 8.89 percent. This is a 44.82 percent increase over sales of $49.324 million the same period last year.